The Oxford/AstraZeneca CCP virus vaccine is linked to “slightly increased risk of some bleeding disorders,” British researchers have found. Through an analysis of people who received a first dose of the AstraZeneca or Pfizer/BioNTech vaccine, researchers at the University of Edinburgh found a small increased risk of an autoimmune bleeding disorder known as immune thrombocytopenic purpura (ITP) associated with the AstraZeneca vaccine. Professor Aziz Sheikh and his colleagues examined cases of vaccine-related bleeding and vascular events among 2.53 million adults in Scotland who received their first doses of vaccines between December and April. They found that the AstraZeneca jab was associated with a slightly increased risk of ITP up to 27 days after vaccination. The disorder can cause minor bruising in some patients and excessive bleeding and long-term illness in others. The analysis, which is published in Nature Medicine, also found very small increased risks of other arterial blood clot …